Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02294552 is registered in ClinicalTrials.gov with Ivan S Moiseev as lead sponsor.

NCT NCT02294552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02294552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Ivan S Moiseev
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
November 30, 2017
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, immune system diseases, lymphoma, myelodysplastic syndromes